RT Journal Article
SR Electronic
T1 Rosiglitazone increased heart failure but did not differ from metformin plus sulphonylurea for other CV outcomes at interim analysis
JF Evidence Based Medicine
JO Evid Based Med
FD BMJ Publishing Group Ltd
SP 170
OP 170
DO 10.1136/ebm.12.6.170
VO 12
IS 6
YR 2007
UL http://ebm.bmj.com/content/12/6/170.abstract
AB